Upcoming FDA decision · October 1, 2026
Belumosudil PDUFA date: FDA decision expected October 1, 2026
8 days to goGSK plc (GSK) →
The FDA is expected to decide on Belumosudil from GSK plc in chronic graft-versus-host disease by the PDUFA target action date of October 1, 2026. For chronic graft-versus-host disease. NDA filing. Extracted from SEC filing: 6-K
A PDUFA date is the FDA's target deadline to complete its review of a drug application — approval, a complete response letter (CRL), or an extension are all possible. What is a PDUFA date? This page is research information, not financial advice.
October 1
Target action date
NDA
Stage
Detected
Date confidence
—
FDA designations